UNSPSC 51172809: Benzocaine/chlorobutanol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.

UNSPSC 51172809 Benzocaine/chlorobutanol, a Commodity code, covers pharmaceutical active ingredients and formulated products supplied to state and local government facilities through cooperative purchasing agreements. State and local governments procure benzocaine and chlorobutanol—topical anesthetics and antimicrobial agents used in over-the-counter products, wound care, and clinical applications—primarily through multistate cooperative purchasing vehicles that aggregate demand across member states and their subordinate agencies, including departments, school districts, and healthcare facilities. Solicitations under this code typically require vendors to supply products through designated authorized wholesalers, maintain cGMP and Drug Supply Chain Security Act (DSCSA) compliance, and accept net-price or WAC-minus pricing structures. Issuing bodies are predominantly state procurement offices administering cooperative purchasing alliances and, by extension, the local and regional government members that contract through them; individual state or local RFPs for these products are less common than cooperative vehicle awards.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota, Oregon, and other MMCAP member jurisdictions. Awarded vendors must provide comprehensive pricing for identified pharmaceutical products with specific National Drug Codes, demonstrate contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, or Morris & Dickson Co.), and accept a 3 percent administrative fee on all contract purchases. The evaluation weights pricing competitiveness at 75 percent, with the remaining 25 percent distributed across fixed pricing, administrative compliance, EDI capability, and administrative-fee acceptance. The contract term is two years for new vendors with optional extensions, and all products must be available in the marketplace by May 15, 2026, with the resulting agreements effective July 1, 2026.